Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.56 |
| ▸ | NOS2 | P35228 | 6/20 | 0.56 |
| ▸ | NOS3 | P29474 | 4/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9362866 | 1.00 | NOS1 (0.56) | NOS1NOS2NOS3ENPP2TSHR | |
| SCHEMBL28448458 | 0.88 | MEN1 (0.55) | NOS1NOS2NOS3ENPP2CHRNA7 | |
| SCHEMBL29832640 | 0.88 | MEN1 (0.55) | NOS1NOS2NOS3ENPP2CHRNA7 | |
| SCHEMBL28448456 | 0.87 | MAPT (0.53) | NOS1NOS2NOS3ENPP2TSHR | |
| SCHEMBL29832620 | 0.87 | MAPT (0.53) | NOS1NOS2NOS3ENPP2TSHR | |
| SCHEMBL30403224 | 0.82 | NOS1 (0.43) | NOS1NOS2NOS3ENPP2CHRNA7 | |
| SCHEMBL1157243 | 0.82 | NOS1 (0.53) | NOS1NOS2NOS3ENPP2TSHR | |
| SCHEMBL3542545 | 0.81 | NOS1 (0.49) | NOS1NOS2NOS3ENPP2TSHR | |
| SCHEMBL28845413 | 0.81 | NOS1 (0.49) | NOS1NOS2NOS3ENPP2TSHR | |
| SCHEMBL10592704 | 0.81 | NOS1 (0.45) | NOS1NOS2NOS3ENPP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2741731-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2741731-A1 | ENCAPSULATES | The Procter and Gamble Company (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | disclosed |
| WO-2013022949-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-0398472-B1 | Biodegradable polyurethanes | ONO PHARMACEUTICAL CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5225514-A | Azo containing polyurethanes for drug delivery to the large intestines | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | NOS1 3213/4885NOS2 2680/4885NOS3 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.